Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells”.

Bibliographic Details

Published in:	Journal for immunotherapy of cancer 2019-11, Vol.7 (1), p.285-285, Article 285
Main Authors:	Florou, Vaia, Rosenberg, Andrew E., Wieder, Eric, Komanduri, Krishna V., Kolonias, Despina, Uduman, Mohamed, Castle, John C., Buell, Jennifer S., Trent, Jonathan C., Wilky, Breelyn A.
Format:	Article
Language:	eng
Subjects:	Angiosarcoma Antibodies Correction Immunoglobulin G Ipilimumab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!